DelveInsight added a report on “Familial Chylomicronemia Syndrome Market“. It covers an overview, its causes, signs and symptoms, and therapies. Major players are involved in de… Read More

Advancing RNA-Targeted Therapies: A Phase 1 Clinical Perspective on Oligos and Beyond… Read More

Small nucleic acid-based drugs, namely oligonucleotide drugs, are short-chain nucleic acids consisting of dozens of nucleotides in series. At present, most oligonucleotide drugs are obtained… Read More

With the continuous development of molecular biology technology, the relationship between gene mutations and diseases has gained more and more in-depth understanding. Nucleic acids have attr… Read More

Health Canada grants priority review for volanesorsen NDS filing Volanesorsen could be the first approved treatment for patients with FCS OTTAWA, Sept. 12, 2017 (GLOBE NEWSWIRE) — Akce… Read More

OpenClipart-Vectors / Pixabay Slowly at first, then accelerating recently in its domestic and global footprint in drug research and regulation, China and its National Medical Products Admini… Read More

Non-renewal of Glybera and launch of Volanesorsen to govern the total Familial Chylomicronemia Syndrome treatment market growth Read More

Akcea Therapeutics (UNKNOWN:AKCA) Price Target & New Coverage by Wells Fargo EU: Akcea Therapeutics (UNKNOWN:AKCA) coverage was was initiated with a Outperform rating and $27.00 price… Read More